L. Zecchinon, T. Fett, P. Vanden Bergh, D. Desmecht
{"title":"Bind another day: The LFA-1/ICAM-1 interaction as therapeutic target","authors":"L. Zecchinon, T. Fett, P. Vanden Bergh, D. Desmecht","doi":"10.1016/j.cair.2006.09.004","DOIUrl":null,"url":null,"abstract":"<div><p>Lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18, α<sub>L</sub>β<sub>2</sub>) actively contributes to the molecular interactions responsible for normal functions of the immune system but is also associated to several diseases from various etiology (genetic, bacterial, viral, neoplastic, allergic, and autoimmune). In this way, the interaction between lymphocyte function-associated antigen-1 and its major ligand intercellular adhesion molecule-1 (ICAM-1 or CD54) has been extensively studied, leading to the development of therapeutic antibodies, peptides, and small inhibitory molecules.</p></div>","PeriodicalId":89340,"journal":{"name":"Clinical and applied immunology reviews","volume":"6 3","pages":"Pages 173-189"},"PeriodicalIF":0.0000,"publicationDate":"2006-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cair.2006.09.004","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and applied immunology reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S152910490600050X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9
Abstract
Lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18, αLβ2) actively contributes to the molecular interactions responsible for normal functions of the immune system but is also associated to several diseases from various etiology (genetic, bacterial, viral, neoplastic, allergic, and autoimmune). In this way, the interaction between lymphocyte function-associated antigen-1 and its major ligand intercellular adhesion molecule-1 (ICAM-1 or CD54) has been extensively studied, leading to the development of therapeutic antibodies, peptides, and small inhibitory molecules.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
